CL2013000400A1 - Conjugate of granulocyte colony stimulating factor (g-csf) with polyethylene glycol; pharmaceutical composition that contains it; and use for the prophylaxis or treatment of leukopenia. - Google Patents

Conjugate of granulocyte colony stimulating factor (g-csf) with polyethylene glycol; pharmaceutical composition that contains it; and use for the prophylaxis or treatment of leukopenia.

Info

Publication number
CL2013000400A1
CL2013000400A1 CL2013000400A CL2013000400A CL2013000400A1 CL 2013000400 A1 CL2013000400 A1 CL 2013000400A1 CL 2013000400 A CL2013000400 A CL 2013000400A CL 2013000400 A CL2013000400 A CL 2013000400A CL 2013000400 A1 CL2013000400 A1 CL 2013000400A1
Authority
CL
Chile
Prior art keywords
leukopenia
prophylaxis
csf
conjugate
treatment
Prior art date
Application number
CL2013000400A
Other languages
Spanish (es)
Inventor
Dmitriy Valentinovich Morozov
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Elena Leonidovna Morozova
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of CL2013000400A1 publication Critical patent/CL2013000400A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugado de factor estimulante de colonia granulocito (G-CSF) con polietilenglicol; composición farmacéutica que lo contiene; y uso para la profilaxis o tratamiento de leucopenia.Conjugate of granulocyte colony stimulating factor (G-CSF) with polyethylene glycol; pharmaceutical composition containing it; and use for the prophylaxis or treatment of leukopenia.

CL2013000400A 2010-08-13 2013-02-08 Conjugate of granulocyte colony stimulating factor (g-csf) with polyethylene glycol; pharmaceutical composition that contains it; and use for the prophylaxis or treatment of leukopenia. CL2013000400A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent

Publications (1)

Publication Number Publication Date
CL2013000400A1 true CL2013000400A1 (en) 2013-07-26

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000400A CL2013000400A1 (en) 2010-08-13 2013-02-08 Conjugate of granulocyte colony stimulating factor (g-csf) with polyethylene glycol; pharmaceutical composition that contains it; and use for the prophylaxis or treatment of leukopenia.

Country Status (18)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
PH (1) PH12012502426A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
KR20160113302A (en) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 Compositions and methods for treating neutropenia
JP6742300B2 (en) 2014-07-14 2020-08-19 ジェンノヴァ バイオファーマシューティカルズ リミテッド Novel process for purification of rHu-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
CN115297844A (en) * 2020-03-17 2022-11-04 德拉格雷丘尔公司 Liquid formulation of GM-CSF for inhalation
JP2023518412A (en) * 2020-03-20 2023-05-01 アムジェン インコーポレイテッド Determination of the free N-terminus of pegfilgrastim using acid protease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
MX2008009125A (en) * 2006-01-18 2008-10-23 Qps Llc Pharmaceutical compositions with enhanced stability.
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc MODIFIED RIBONUCLEASES

Also Published As

Publication number Publication date
DOP2013000003A (en) 2013-07-31
PH12012502426A1 (en) 2021-06-02
CR20130020A (en) 2013-02-20
EA019043B1 (en) 2013-12-30
SG187572A1 (en) 2013-03-28
RU2446173C1 (en) 2012-03-27
RS20130094A1 (en) 2013-08-30
MY160732A (en) 2017-03-15
KR101549457B1 (en) 2015-09-02
PE20131085A1 (en) 2013-10-10
EA201101035A1 (en) 2012-02-28
ECSP13012399A (en) 2013-05-31
MA34525B1 (en) 2013-09-02
CU24139B1 (en) 2015-12-23
NI201300007A (en) 2014-05-26
CO6670557A2 (en) 2013-05-15
CN103140499B (en) 2014-12-17
WO2012021088A1 (en) 2012-02-16
CU20130012A7 (en) 2013-04-19
CN103140499A (en) 2013-06-05
KR20130043167A (en) 2013-04-29

Similar Documents

Publication Publication Date Title
CL2013000400A1 (en) Conjugate of granulocyte colony stimulating factor (g-csf) with polyethylene glycol; pharmaceutical composition that contains it; and use for the prophylaxis or treatment of leukopenia.
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
CL2012002189A1 (en) Compounds derived from substituted pyrrolidine-2-carboxamides; mdm2-p53 interaction inhibitors; pharmaceutical composition; and its use for the treatment of cancer, particularly solid tumors.
CL2013000016A1 (en) Compounds derived from imidazopyridine; preparation procedure; Pharmaceutical composition and its use in the treatment of cancer.
GT201200321A (en) DERIVATIVES OF HETEROARIL IMIDAZOLONA AS JAK INHIBITORS
MY162146A (en) Pharmaceutical composition
CL2014001829A1 (en) Compounds derived from indolizine; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer.
CL2008001633A1 (en) Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
CL2011000527A1 (en) Compounds derived from benzofuran; pharmaceutical composition that includes them; and their use in the treatment of hepatitis c.
CR20120158A (en) IMINOTIADIAZINE DIÒXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE.
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
CL2010001637A1 (en) Compounds derived from isoindolones; pharmaceutical composition comprising them; and its use as mek kinase inhibitors to treat hyperproliferative and / or inflammatory diseases such as cancer, rheumatoid arthritis among others.
CL2013001338A1 (en) Compounds derived from substituted benzothiene-pyridines, hiv replication inhibitors; pharmaceutical composition that includes them; pharmaceutical combination; pharmaceutical kit; and its use for the treatment of hiv.
CL2011001232A1 (en) Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
BR112014021531A2 (en) compound, pharmaceutical composition and uses thereof
CL2014001865A1 (en) Phosphate derived compounds; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer.
UY32918A (en) NEW COMPOUNDS OF 2-PIRIDONA
BR112014011254A2 (en) 2-thiopyrimidinones
AR125920A2 (en) COMPOSITIONS COMPRISING VORTIOXETINE AND DONEPEZIL
BR112018002983A2 (en) composition comprising a lactam and an alcohol
UY32704A (en) COMPOUNDS OF 2,3-DIHIDRO-1H-INDENO
BR112013014189A2 (en) pharmaceutical composition comprising transcinamaldehyde and its use in the treatment of infections
DOP2015000298A (en) NEW COMPOUNDS FOR CANCER TREATMENT
UY32520A (en) COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR